Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.

Post-Marketing Studies play an integral role in gathering information about safety and efficacy on a large scale. However, monitoring adverse events and patient-reported outcomes in a real-world setting can be challenging.

The DP aims to collaborate with pharmaceutical and biotechnology companies by providing access to our customizable software Scarletred®Vision for exploratory or early-stage clinical studies at a more attractive price point.

Digitalization and telemedicine have shown significant advancements in the medical industry. Still, clinical research will continue to need high-quality tools to conduct trials efficiently and decrease strain on patients.